IL96636A - History of piperidine Process for preparation and pharmaceutical preparations containing them - Google Patents
History of piperidine Process for preparation and pharmaceutical preparations containing themInfo
- Publication number
- IL96636A IL96636A IL9663690A IL9663690A IL96636A IL 96636 A IL96636 A IL 96636A IL 9663690 A IL9663690 A IL 9663690A IL 9663690 A IL9663690 A IL 9663690A IL 96636 A IL96636 A IL 96636A
- Authority
- IL
- Israel
- Prior art keywords
- formula
- compound
- preparation
- compound according
- carbon atoms
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 230000036592 analgesia Effects 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 230000000202 analgesic effect Effects 0.000 claims description 13
- 230000003444 anaesthetic effect Effects 0.000 claims description 10
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 206010002091 Anaesthesia Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 230000037005 anaesthesia Effects 0.000 claims description 4
- 238000001949 anaesthesia Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 229960000482 pethidine Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940124326 anaesthetic agent Drugs 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- QKHMFBKXTNQCTM-UHFFFAOYSA-N norpethidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCNCC1 QKHMFBKXTNQCTM-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- SJSSSWXOQBSRTP-UHFFFAOYSA-N 1-(2-ethoxyethyl)-4-phenylpiperidine-4-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(CCOCC)CCC1(C(O)=O)C1=CC=CC=C1 SJSSSWXOQBSRTP-UHFFFAOYSA-N 0.000 description 1
- ISEBVOHVEGXNBW-UHFFFAOYSA-N 1-(4-ethoxybutyl)-4-phenylpiperidine-4-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(CCCCOCC)CCC1(C(O)=O)C1=CC=CC=C1 ISEBVOHVEGXNBW-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- MMYKTRPLXXWLBC-UHFFFAOYSA-N 1-bromo-2-ethoxyethane Chemical compound CCOCCBr MMYKTRPLXXWLBC-UHFFFAOYSA-N 0.000 description 1
- AZSSSYFLDBQDBQ-UHFFFAOYSA-N 1-butyl-4-phenylpiperidine-4-carboxylic acid Chemical compound C1CN(CCCC)CCC1(C(O)=O)C1=CC=CC=C1 AZSSSYFLDBQDBQ-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- IXRDURXALZYREB-UHFFFAOYSA-N 1-chloro-4-ethoxybutane Chemical compound CCOCCCCCl IXRDURXALZYREB-UHFFFAOYSA-N 0.000 description 1
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- DMCVVFIWYIKAEJ-UHFFFAOYSA-N 4-phenylpiperidine-4-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCNCC1 DMCVVFIWYIKAEJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZJVHJWSKZOLGCZ-UHFFFAOYSA-N n-butyl-1-methyl-4-phenylpiperidine-4-carboxamide Chemical compound C=1C=CC=CC=1C1(C(=O)NCCCC)CCN(C)CC1 ZJVHJWSKZOLGCZ-UHFFFAOYSA-N 0.000 description 1
- RZKLJVMZMYEYCM-UHFFFAOYSA-N n-ethyl-1-hexyl-4-phenylpiperidine-4-carboxamide Chemical compound C1CN(CCCCCC)CCC1(C(=O)NCC)C1=CC=CC=C1 RZKLJVMZMYEYCM-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8904298A SE8904298D0 (sv) | 1989-12-21 | 1989-12-21 | New compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL96636A0 IL96636A0 (en) | 1991-09-16 |
| IL96636A true IL96636A (en) | 1994-11-28 |
Family
ID=20377821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9663690A IL96636A (en) | 1989-12-21 | 1990-12-11 | History of piperidine Process for preparation and pharmaceutical preparations containing them |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US5227389A (fr) |
| EP (1) | EP0506778B1 (fr) |
| JP (1) | JP2656152B2 (fr) |
| KR (1) | KR0179382B1 (fr) |
| CN (1) | CN1037841C (fr) |
| AT (1) | ATE138650T1 (fr) |
| AU (1) | AU647068B2 (fr) |
| BG (1) | BG60912B1 (fr) |
| BR (1) | BR1100379A (fr) |
| CA (1) | CA2069608C (fr) |
| CZ (1) | CZ278035B6 (fr) |
| DE (1) | DE69027221T2 (fr) |
| DK (1) | DK0506778T3 (fr) |
| DZ (1) | DZ1468A1 (fr) |
| EG (1) | EG19361A (fr) |
| ES (1) | ES2087280T3 (fr) |
| FI (1) | FI100881B (fr) |
| HK (1) | HK22997A (fr) |
| HR (1) | HRP920591B1 (fr) |
| HU (1) | HU213110B (fr) |
| IE (1) | IE74855B1 (fr) |
| IL (1) | IL96636A (fr) |
| IS (1) | IS1664B (fr) |
| LT (1) | LT4005B (fr) |
| LV (2) | LV10949B (fr) |
| NO (1) | NO178858C (fr) |
| NZ (1) | NZ236293A (fr) |
| PL (1) | PL163591B1 (fr) |
| PT (1) | PT96303B (fr) |
| RO (1) | RO112864B1 (fr) |
| RU (1) | RU2039043C1 (fr) |
| SA (1) | SA91110209B1 (fr) |
| SE (1) | SE8904298D0 (fr) |
| SG (1) | SG46413A1 (fr) |
| SI (1) | SI9012346B (fr) |
| SK (1) | SK278283B6 (fr) |
| UA (1) | UA26403A (fr) |
| WO (1) | WO1991009845A1 (fr) |
| YU (1) | YU48086B (fr) |
| ZA (1) | ZA909903B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3916092B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
| SE9400447D0 (sv) * | 1994-02-11 | 1994-02-11 | Astra Ab | New compounds |
| SE9404438D0 (sv) * | 1994-12-21 | 1994-12-21 | Astra Ab | New process |
| US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
| US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
| US20020102291A1 (en) * | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| JP4280073B2 (ja) * | 2001-04-12 | 2009-06-17 | ファーマコペイア ドラッグ ディスカバリー， インコーポレイテッド | Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン |
| JP2006511554A (ja) * | 2002-12-13 | 2006-04-06 | スミスクライン ビーチャム コーポレーション | Ｃｃｒ５アンタゴニストとしてのピペリジン誘導体 |
| WO2008045564A2 (fr) * | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Composés de carboxamide et leur utilisation |
| RU2010128543A (ru) | 2007-12-11 | 2012-01-20 | Сайтопатфайндер, Инк. (Jp) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов |
| US8473062B2 (en) | 2008-05-01 | 2013-06-25 | Autonomic Technologies, Inc. | Method and device for the treatment of headache |
| US8412336B2 (en) | 2008-12-29 | 2013-04-02 | Autonomic Technologies, Inc. | Integrated delivery and visualization tool for a neuromodulation system |
| US9320908B2 (en) | 2009-01-15 | 2016-04-26 | Autonomic Technologies, Inc. | Approval per use implanted neurostimulator |
| US8494641B2 (en) | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
| EP3914246A1 (fr) | 2019-01-22 | 2021-12-01 | ICM (Institut du Cerveau et de la Moelle Épinière) | Anesthésique local pour le traitement de symptômes neurologiques résultant de dysfonctionnements cérébraux |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE96980C1 (fr) | ||||
| US2486796A (en) * | 1943-06-25 | 1949-11-01 | Ciba Pharm Prod Inc | Esters of 1-alkyl-4-hydroxyphenylpiperidyl-4-ketones |
| US3334106A (en) * | 1964-10-20 | 1967-08-01 | Aldrich Chem Co Inc | N(aryl)n(hydrocarbyl)-omega-(4-phenyl-4-piperidinocarbonylheteroamine) alkanoamide |
| US3539580A (en) * | 1967-06-26 | 1970-11-10 | Janssen Pharm | 4-aryl-4-aminoalkoxy-piperidines |
| CH501622A (de) * | 1968-12-20 | 1971-01-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Piperidinderivaten |
| US3737538A (en) * | 1968-12-30 | 1973-06-05 | Ciba Geigy Corp | Antitussive compositions and method with isonipecotic acid derivatives |
| FR2156470A2 (en) * | 1971-10-21 | 1973-06-01 | Synthelabo | 1-(3,3-diphenyl-1-propyl)-4-aryl-piperidines - as analgesics spasmolytic and anti-tussive agents |
| ZA899436B (en) * | 1988-12-12 | 1990-08-29 | Ciba Geigy | Piperidine derivatives |
| US5100903A (en) * | 1989-05-12 | 1992-03-31 | Anaquest, Inc. | N-aryl-n-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds |
-
1989
- 1989-12-21 SE SE8904298A patent/SE8904298D0/xx unknown
-
1990
- 1990-11-30 NZ NZ236293A patent/NZ236293A/xx unknown
- 1990-12-10 ZA ZA909903A patent/ZA909903B/xx unknown
- 1990-12-11 IL IL9663690A patent/IL96636A/en not_active IP Right Cessation
- 1990-12-12 DZ DZ900223A patent/DZ1468A1/fr active
- 1990-12-12 SI SI9012346A patent/SI9012346B/sl not_active IP Right Cessation
- 1990-12-12 YU YU234690A patent/YU48086B/sh unknown
- 1990-12-17 HU HU9202044A patent/HU213110B/hu unknown
- 1990-12-17 AT AT91901571T patent/ATE138650T1/de not_active IP Right Cessation
- 1990-12-17 SG SG1996004491A patent/SG46413A1/en unknown
- 1990-12-17 RO RO92-0832A patent/RO112864B1/ro unknown
- 1990-12-17 DE DE69027221T patent/DE69027221T2/de not_active Expired - Fee Related
- 1990-12-17 EP EP91901571A patent/EP0506778B1/fr not_active Expired - Lifetime
- 1990-12-17 KR KR1019920701484A patent/KR0179382B1/ko not_active IP Right Cessation
- 1990-12-17 CA CA002069608A patent/CA2069608C/fr not_active Expired - Fee Related
- 1990-12-17 DK DK91901571.9T patent/DK0506778T3/da active
- 1990-12-17 JP JP3501896A patent/JP2656152B2/ja not_active Expired - Fee Related
- 1990-12-17 IE IE453490A patent/IE74855B1/en not_active IP Right Cessation
- 1990-12-17 IS IS3659A patent/IS1664B/is unknown
- 1990-12-17 AU AU69783/91A patent/AU647068B2/en not_active Ceased
- 1990-12-17 ES ES91901571T patent/ES2087280T3/es not_active Expired - Lifetime
- 1990-12-17 UA UA5052485A patent/UA26403A/uk unknown
- 1990-12-17 WO PCT/SE1990/000818 patent/WO1991009845A1/fr active IP Right Grant
- 1990-12-20 PT PT96303A patent/PT96303B/pt active IP Right Grant
- 1990-12-20 EG EG74690A patent/EG19361A/xx active
- 1990-12-21 SK SK6581-90A patent/SK278283B6/sk unknown
- 1990-12-21 US US07/633,246 patent/US5227389A/en not_active Expired - Lifetime
- 1990-12-21 CZ CS906581A patent/CZ278035B6/cs not_active IP Right Cessation
- 1990-12-21 PL PL90288409A patent/PL163591B1/pl not_active IP Right Cessation
- 1990-12-21 CN CN90106009A patent/CN1037841C/zh not_active Expired - Fee Related
-
1991
- 1991-01-09 SA SA91110209A patent/SA91110209B1/ar unknown
-
1992
- 1992-06-17 NO NO922380A patent/NO178858C/no unknown
- 1992-06-17 FI FI922806A patent/FI100881B/fi not_active IP Right Cessation
- 1992-06-19 BG BG96513A patent/BG60912B1/bg unknown
- 1992-06-19 RU SU925052485A patent/RU2039043C1/ru not_active IP Right Cessation
- 1992-09-29 HR HRP-2346/90A patent/HRP920591B1/xx not_active IP Right Cessation
-
1993
- 1993-07-12 US US08/090,416 patent/US5360805A/en not_active Expired - Lifetime
- 1993-08-27 LV LVP-93-1042A patent/LV10949B/lv unknown
- 1993-12-30 LT LTIP1731A patent/LT4005B/lt not_active IP Right Cessation
-
1996
- 1996-07-17 LV LV960262A patent/LV5766B4/xx unknown
-
1997
- 1997-02-27 HK HK22997A patent/HK22997A/xx not_active IP Right Cessation
- 1997-04-30 BR BR1100379-0A patent/BR1100379A/pt active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3833116B2 (ja) | ビフェニル誘導体、その製法及び薬剤としての使用 | |
| US5360805A (en) | Substituted 4-phenyl-4-piperidinecarboxamides with both local anaesthetic and analgesic effect as well as processes for their preparation | |
| JP2895145B2 (ja) | 鎮痛剤として用いられるｎ―フエニル―ｎ―（４―ピペリジニル）アミド | |
| JPH09505277A (ja) | ４−ピペリドンのカルベン添加／アミノリシスによるスフェンタニル誘導体の製造方法 | |
| CH643554A5 (de) | Verfahren zur herstellung von piperidinopropanolderivaten. | |
| EP0743940B1 (fr) | Nouveaux composes a effet analgesique et a effet anesthesique local | |
| US6362203B1 (en) | 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same | |
| US10844014B2 (en) | Intermediates for the preparation of remifentanil hydrochloride | |
| US20060094877A1 (en) | Process for preparation of benzylpiperidine compounds | |
| EP0079740B1 (fr) | Anthraniloyloxyalcanoates | |
| DD259189A5 (de) | Verfahren zur herstellung neuer hydropyridin-derivate | |
| JP2002284763A (ja) | ベンジルピペリジン化合物の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| HC | Change of name of proprietor(s) | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |